We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Made in China

6 November 2019 By Katrina Hamlin

Feihe has priced shares at the bottom of the range, valuing the infant-formula maker at $8.6 bln. That’s partly down to Hong Kong’s lukewarm market. But it also reflects the risks for a homegrown brand sourcing a premium product locally in a country with a history of food scares.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)